Health Secretary Robert F. Kennedy Jr. endorsed the expanded use of RSV vaccines for people 50 through 59 years old who are ...

Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Value Stocks to Buy According to Billionaires. The company announced that ...

MPV tends to hit hardest in young children, older adults and people with weakened immune systems. A virologist explains.

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

RSV seasons ended earlier than usual in 2022-23 and 2023-24, and typical human hMPV circulation patterns have returned since the COVID-19 pandemic.

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

Although the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) was scheduled to vote June 25 on recommendations ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) has blessed Merck’s new respiratory syncytial virus (RSV) shot ...

For the 2024-25 updated COVID vaccine against emergency department and urgent care encounters, the CDC found 79% ...

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated ...

The ACIP meeting was the first time the eight new members convened since they were appointed by Kennedy on June 11.

RSV is the focus of a new national pediatric guideline in China aimed at standardizing diagnosis, treatment, and prevention strategies for respiratory tract infections in children ...